Perrigo Company plc Proceeds from Sale of Intangible Assets
Perrigo Company plc (PRGO) reported Proceeds from Sale of Intangible Assets of $2.20 billion for the 3-month period ending 2017-04-01, per its 10-Q filed 2017-05-30.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfIntangibleAssets · last filed 2017-05-30
- Perrigo Company plc proceeds from sale of intangible assets for the quarter ending 2017-04-01 was $2.20B.
- Perrigo Company plc proceeds from sale of intangible assets for the quarter ending 2016-04-02 was $0.00.
| Period end | Proceeds from Sale of Intangible Assets 3 month |
|---|---|
| 2017-04-01 | $2.20B 10-Q · filed 2017-05-30 |
| 2016-04-02 | $0.00 10-Q · filed 2017-05-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |